Journal article
New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk
European heart journal. Cardiovascular pharmacotherapy, Vol.4(2), pp.119-127
04/01/2018
DOI: 10.1093/ehjcvp/pvx031
PMID: 29194462
Abstract
The very high occurrence of cardiovascular events presents a major public health issue, because treatment remains suboptimal. Lowering LDL cholesterol (LDL-C) with statins or ezetimibe in combination with a statin reduces major adverse cardiovascular events. The cardiovascular risk reduction in relation to the absolute LDL-C reduction is linear for most interventions without evidence of attenuation or increase in risk at low LDL-C levels. Opportunities for innovation in dyslipidaemia treatment should address the substantial risk of lipid-associated cardiovascular events among patients optimally treated per guidelines but who cannot achieve LDL-C goals and who could benefit from additional LDL-C-lowering therapy or experience side effects of statins. Fresh approaches are needed to identify promising drug targets early and develop them efficiently. The Cardiovascular Round Table of the European Society of Cardiology (ESC) convened a workshop to discuss new lipid-lowering strategies for cardiovascular risk reduction. Opportunities to improve treatment approaches and the efficient study of new therapies were explored. Circulating biomarkers may not be fully reliable proxy indicators of the relationship between treatment effect and clinical outcome. Mendelian randomization studies may better inform development strategies and refine treatment targets before Phase 3. Trials should match the drug to appropriate lipid and patient profile, and guidelines may move towards a precision-based approach to individual patient management. Stakeholder collaboration is needed to ensure continued innovation and better international coordination of both regulatory aspects and guidelines. It should be noted that risk may also be addressed through increased attention to other risk factors such as smoking, hypertension, overweight, and inactivity.
Details
- Title: Subtitle
- New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk
- Creators
- Ian Graham - Trinity College, Adelaide Health Foundation, Tallaght Hospital, Dublin 24, IrelandChuck Shear - Global Product Development/Internal Medicine, Pfizer, Inc., 235 E. 42nd Street, New York, New York 10017, NY, USAPieter De Graeff - Department of Pharmacy and Clinical Pharmacology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The NetherlandsCaroline Boulton - Novartis Pharma AG, Asklepios 8, 4056 Basel, SwitzerlandAlberico L Catapano - Department of Pharmacological and Biomolecular Sciences and Multimedica IRCCS, University of Milan, via Balzaretti 9, 20133 Milano, ItalyWendy Gattis Stough - Departments of Clinical Research and Pharmacy Practice, Campbell University College of Pharmacy and Health Sciences, 217 Main St., Buies Creek, NC 27506, USAStefan C Carlsson - Cardiovascular Pharmacology, AstraZeneca, Pepparredsleden 1, SE-431 83 Mölndal, SwedenGuy De Backer - Department of Public Health, Faculty of Medicine and Health Sciences, Ghent University, University Hospital, K3, 4th floor, De Pintelaan 185, B9000 Ghent, BelgiumJoseph Emmerich - Université Paris-Descartes, Cochin-Hôtel Dieu Hospital, French National Agency for Medicines and Health Products Safety, 143/147, Boulevard, Anatole France 93285, Saint-Denis, FranceScott Greenfeder - Regulatory Affairs, Daiichi-Sankyo, 211 Mt. Airy Road, Basking Ridge, NJ 07920, USAAlbert M Kim - Internal Medicine Research Unit, Pfizer, Inc., 1 Portland St., 4th floor, Cambridge, MA 02139, USADominik Lautsch - Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USATu Nguyen - SanofiSteven E Nissen - Department of Cardiovascular Medicine, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USAKrishna Prasad - Licensing Division, United Kingdom Medicines and Healthcare Products Regulatory Agency, 151 Buckingham Palace Road, London SW1W 9SZ, UKKausik K Ray - Department of Primary Care and Public Health, Imperial College, 323 Reynolds Building, Room 320, Charing Cross Hospital, London W68RF, UKJennifer G Robinson - Department of Epidemiology, College of Public Health, University of Iowa, 145 N. Riverside Dr S455 CPHB, Iowa City, IA 52242, USAWilliam J Sasiela - Regeneron Pharmaceuticals, 777 Old Saw Mill River Road, Tarrytown, NY 10591, USAKarsten Bruins Slot - Oslo University Hospital, Ullevål, Medical Department, Postboks 4956 Nydalen, 0424 Oslo, NorwayErik Stroes - Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The NetherlandsTom Thuren - Novartis Pharma AG, Asklepios 8, 4056 Basel, SwitzerlandBart Van der Schueren - Laboratory of Experimental Medicine and Endocrinology, University of Leuven, Herestraat 49, 3000 Leuven, BelgiumMaja Velkovski-Rouyer - Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USAScott M Wasserman - Amgen, One Amgen Center Drive, MS 38.2.C, Thousand Oaks, CA 91320, USAOlov Wiklund - Wallenberg Laboratory, Sahlgrenska University Hospital, 413 45 Gothenburg, SwedenEmmanouil Zouridakis - Licensing Division, United Kingdom Medicines and Healthcare Products Regulatory Agency, 151 Buckingham Palace Road, London SW1W 9SZ, UKEuropean Society of Cardiology Cardiovascular Roundtable
- Resource Type
- Journal article
- Publication Details
- European heart journal. Cardiovascular pharmacotherapy, Vol.4(2), pp.119-127
- Publisher
- England
- DOI
- 10.1093/ehjcvp/pvx031
- PMID
- 29194462
- ISSN
- 2055-6837
- eISSN
- 2055-6845
- Language
- English
- Date published
- 04/01/2018
- Academic Unit
- Epidemiology; Internal Medicine
- Record Identifier
- 9983995008202771
Metrics
14 Record Views